Skip to content
Calculator

Part of the skin and hair peptide hub: every topical and cosmetic peptide we cover, with its evidence grade.

Evidence: LowPeptide Research Only Cosmetic & Skin

Caprooyl Tetrapeptide-3

also known as: Hexanoyl-Gly-Gln-Pro-Arg

Hexanoyl-GQPR, a short-chain acylated cosmetic tetrapeptide. PubMed holds no study of it.

Caprooyl tetrapeptide-3 is a synthetic peptide, a hexanoyl group on Gly-Gln-Pro-Arg (PubChem's record, under its INCI name). It is sold as an anti-ageing skin-care ingredient, but a title-and-abstract search of PubMed for its INCI name finds no study of it. It is not a drug.

No dosing data yet Details ↓

Mechanism of action

Not established: no published study describes its action.

Primary uses

Typical dosing

Not established for human use

No published study states an amount of this ingredient used on skin, and a supplier's use level is not a source on this site, so none is given.

Regulatory status

Not a drug: PubChem lists it under its INCI name as a cosmetic ingredient (CID 71599291). Drugs@FDA and the EMA medicines list hold no record for it (searched October 28, 2026).

Status as of this entry's last review, October 28, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What we checked

Caprooyl Tetrapeptide-3 is a cosmetic peptide ingredient with little or no published literature; this section records what can be checked.

Identity, computed

Structurehexanoyl-Gly-Gln-Pro-Arg, free acid (PubChem's IUPAC name, CID 71599291)
FormulaC24H42N8O7 (PubChem)
Molecular weight554.6 g/mol (PubChem)

The calculator used elsewhere on this site does not handle this N-terminal acyl group, so the formula and weight are PubChem's, not computed here.

Regulatory status, read October 28, 2026

Drugs@FDA: 0 records for “caprooyl tetrapeptide-3”. EMA medicines list: 0 records for “caprooyl tetrapeptide-3”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 80 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on October 28, 2026.

What we looked for and did not find

No published study of any kind, no registry record and no drug approval.

SourceQueryResults, October 28, 2026What it was
PubMed("tetrapeptide-3"[tiab] AND caprooyl[tiab])0name matched word by word in title/abstract (a phrase search misses hyphen-numbered names)
ClinicalTrials.govcaprooyl tetrapeptide-30
Drugs@FDA (openFDA)caprooyl tetrapeptide-30
EMA medicines listcaprooyl tetrapeptide-30

References

  1. [other] PubChem CID 71599291, Caprooyl Tetrapeptide-3: formula C24H42N8O7, molecular weight 554.6. Read October 28, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/71599291

Related peptides

Palmitoyl Tetrapeptide-7

Pal-GQPR, the second peptide in a popular anti-wrinkle blend: studied alone only in a 2026 cell screen and a three-person skin permeation study; its IL-6 claim has no published source.

Palmitoyl Pentapeptide-4

The palmitoylated procollagen fragment sold as Matrixyl (pal-KTTKS): in a 12-week split-face trial in 93 women a moisturiser containing it reduced wrinkles more than the same moisturiser alone. A cosmetic ingredient, not a drug.

Tetrapeptide-21

GEKG, a cosmetic tetrapeptide that raised collagen in skin cells and reduced skin roughness in one small 2011 placebo-controlled study; most later work is about getting it into skin.

Acetyl Tetrapeptide-2

A firming cosmetic peptide sold as Uplevity, sequence undisclosed. Its supplier's claims are unpublished; one hair-lotion trial used it among several actives.

Guides & tools

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.